Windward Bio Seeks Up to $1 Billion Valuation in IPO

The Basel-based drug developer is offering roughly 10.3 million shares priced between $16 and $18 on the Nasdaq under the symbol WWB.

Updated on Nov. 9, 2026 in Healthcare

Windward Bio Seeks Up to $1 Billion Valuation in IPO

Windward Bio Group AG, a Basel, Switzerland-based drug developer, is seeking up to $185.3 million in a US initial public offering targeting a valuation of up to $1 billion. The company will list on the Nasdaq under the symbol WWB, with Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank underwriting the offering.

Why it matters

The offering reflects healthcare's role as an anchor of the fall IPO window, even as choppy markets and rising borrowing costs weigh on listings in other sectors. Windward Bio's pipeline of antibody medicines targets large respiratory and skin conditions.

Windward Bio is selling roughly 10.3 million shares priced between $16 and $18, seeking up to $185.3 million in total. The company has already raised $310 million in equity from Novo Holdings and other healthcare investors, with Sanofi buying $50 million of shares and pre-funded warrants in a private placement.

The players

Windward Bio Group AG

A Basel, Switzerland-based drug developer focused on antibody medicines for asthma, chronic obstructive pulmonary disease and atopic dermatitis.

Sanofi

A French multinational pharmaceutical company that agreed to buy $50 million of Windward Bio shares and pre-funded warrants in a private placement.

Novo Holdings

The investment arm of Novo Nordisk's foundation, which has backed Windward Bio's $310 million in equity financing.

The details

Windward Bio is developing antibody medicines for asthma, chronic obstructive pulmonary disease and atopic dermatitis. The offering is being led by Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank, with listing on the Nasdaq under WWB.

Timeline

  1. November 9, 2026: Windward Bio disclosed its IPO terms, targeting a valuation of up to $1 billion.

  2. Week of November 9, 2026: Rezera is expected to go public in New York following its US roadshow.

Market Landscape

Healthcare has anchored the fall IPO window this year, even as choppy market conditions and rising borrowing costs weigh on listings from other sectors. Windward Bio's offering, alongside Rezera's expected New York debut, shows biotechnology companies continuing to find investor demand in a difficult market.

For investors, the offering provides a chance to buy into a company with a late-stage antibody pipeline at a price range of $16 to $18 per share. Pricing and listing outcomes will shape how other biotech firms approach public markets this season.

The takeaway

Healthcare's continued strength in the fall IPO window signals that investors still reward biotech companies with clinical pipelines even as broader markets stall. Watch how Windward Bio's pricing compares to its $1 billion valuation target.

What happens next

Windward Bio's final offering price and the outcome of its Nasdaq debut under WWB will be determined once the roadshow concludes.

Further reading

Explore more on Healthcare business and industry coverage for context on biotech listings.